Voyager Therapeutics Q1 2024 GAAP EPS $(0.20) Beats $(0.45) Estimate, Sales $19.516M Beat $9.415M Estimate
Portfolio Pulse from Benzinga Newsdesk
Voyager Therapeutics (NASDAQ:VYGR) reported Q1 2024 GAAP EPS of $(0.20), surpassing the $(0.45) estimate, with sales of $19.516M also beating the $9.415M estimate. Despite these beats, both earnings and sales saw significant decreases from the previous year.
May 13, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Voyager Therapeutics reported a significant beat on both EPS and sales estimates for Q1 2024, despite a notable decrease from the previous year's figures.
Beating EPS and sales estimates typically has a positive short-term impact on a company's stock price, as it indicates better-than-expected financial health and operational efficiency. However, the significant decrease from the previous year's figures might temper investor enthusiasm, suggesting a cautious optimism.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100